Task 3.6
Nanobody labelling optimisation for PET and OI...
Description
For OI, nanobodies from Tasks 3.1 and 3.2 will be labelled with IRDye800CW. For PET imaging, we will rely on the versatile experience (both preclinical and clinical) in radiolabelling of small proteins and nanobodies within the consortium (see sectio...
General Design
- Type
- Cohort study
- Start/End data collection
- not available
Organisations
Lead organisations
- EBERHARD KARLS UNIVERSITAET TUEBINGENGermanyhttps://uni-tuebingen.de/en/
- PFIZER LIMITEDUnited Kingdom of Great Britain and Northern Ireland (the)https://www.pfizer.com/
- STICHTING VUMC (P1)Netherlands (the)https://www.vumc.nl/
- TAKEDA DEVELOPMENT CENTRE EUROPE LTDUnited Kingdom of Great Britain and Northern Ireland (the)
- University Medical Centre Groningen (UMCG)Netherlands (the)https://www.umcg.nl/
- VRIJE UNIVERSITEIT BRUSSELBelgiumhttps://www.vub.be/en/home
- WESTFAELISCHE WILHELMSUNIVERSITAET MUENSTERGermanyhttps://www.uni-muenster.de/en/
Networks
Part of networks...